Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 5;7(8):e008150. doi: 10.1161/JAHA.117.008150

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

The forest plot of hazard ratios for each standard‐dose NOAC (apixaban 5 mg twice daily, dabigatran 150 mg twice daily, and rivaroxaban 20 mg once daily) vs low‐dose NOAC (apixaban 2.5 mg twice daily, dabigatran 110 mg twice daily, and rivaroxaban 15/10 mg once daily) comparison. In general, standard‐dose NOACs showed 6 comparable outcomes to low‐dose NOACs. It was noted that standard‐dose apixaban had lower risks of all‐cause mortality compared to low‐dose apixaban. AMI indicates acute myocardial infarction; CI, confidence interval; GIB, gastrointestinal bleeding; HR, hazard ratio; ICH, intracranial hemorrhage; IS/SE, ischemic stroke/systemic embolism; NOAC, non–vitamin K antagonist oral anticoagulant.